[{"notes_id":"1_327","category":"12","subcategory":"0","title":"Asthma: management in adults","body":"In 2024 NICE, the British Thoracic Society and SIGN produced joint guidelines on the management of asthma following many years of conflicting guidelines. The new guidelines represent a major step change in the management of asthma is both diagnosed and treated.<br \/><br \/>For many years patients with asthma were started on a short-acting beta-2 agonist (SABA) inhaler before 'stepping up' to a regular inhaled corticosteroid with a SABA as required. The new guidelines now advocate the use of combined inhalers (ICS + long-acting beta-2 agonist) as reliever therapy or regularly, depending on the severity of asthma. Given the prevalence of asthma, it is likely that doctors will have to deal with patients on 'conventional' asthma treatments for many years to come. The joint guidelines therefore include guidance on how to manage these patients if their current treatment is controlling their symptoms sufficiently.<br \/><br \/><h5 class='notes-heading'>Management of adult patients aged children aged \u2265 12 years with newly diagnosed asthma<\/h5><br \/>Step 1 <a href='https:\/\/www.nice.org.uk\/guidance\/ng245\/chapter\/Recommendations#pharmacological-management-in-people-aged-12-and-over:~:text=and%20over.-,Initial%20management%20of%20newly%20diagnosed%20asthma%20in%20people%20aged%2012%20and%20over,-1.7.1' title='NICE - 2024 Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)' target='_blank' class='badge rounded-pill text-bg-light deeplink'>NICE<\/a><ul><li>a <span class=\"concept\" data-cid=\"12286\">low-dose inhaled corticosteroid (ICS)\/formoterol combination inhaler to be taken as needed for symptom relief<\/span><ul><li>this is termed anti-inflammatory reliever (AIR) therapy<\/li><\/ul><\/li><li>if the patient presents highly symptomatic (for example, regular nocturnal waking) or with a severe exacerbation:<ul><li><span class=\"concept\" data-cid=\"12295\">start treatment with low-dose MART<\/span> (maintenance and reliever therapy, see below)<\/li><li>treat the acute symptoms as appropriate (e.g. a course of oral corticosteroids may be indicated)<\/li><\/ul><\/li><\/ul><br \/>Step 2  <a href='https:\/\/www.nice.org.uk\/guidance\/ng245\/chapter\/Recommendations#pharmacological-management-in-people-aged-12-and-over:~:text=asthma%20management.-,Medicine%20combination%20and%20sequencing%20in%20people%20aged%2012%20and%20over,-For%20guidance%20on' title='NICE - 2024 Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)' target='_blank' class='badge rounded-pill text-bg-light deeplink'>NICE<\/a> <br \/><ul><li><span class=\"concept\" data-cid=\"12287\">a low-dose MART<\/span><ul><li>MART describes using an inhaled corticosteroid (ICS)\/formoterol combination inhaler for daily maintenance therapy and the relief of symptoms as needed, i.e. regularly and as required<\/li><\/ul><\/li><\/ul><br \/>Step 3<br \/><ul><li>a <span class=\"concept\" data-cid=\"12288\">moderate-dose MART<\/span><\/li><\/ul><br \/>Step 4<br \/><ul><li><span class=\"concept\" data-cid=\"12289\">check the fractional exhaled nitric oxide (FeNO) level if available, and the blood eosinophil count<\/span>  <a href='https:\/\/www.nice.org.uk\/guidance\/ng245\/chapter\/Recommendations#pharmacological-management-in-people-aged-12-and-over:~:text=Check%20the%20fractional%20exhaled%20nitric%20oxide%20(FeNO)%20level%20if%20available' title='NICE - 2024 Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)' target='_blank' class='badge rounded-pill text-bg-light deeplink'>NICE<\/a> <ul><li>if <span class=\"concept\" data-cid=\"12290\">either of these is raised, refer to a specialist in asthma care<\/span><\/li><li>if <span class=\"concept\" data-cid=\"12291\">neither FeNO nor eosinophil count is raised, consider a trial of either a leukotriene receptor antagonist (LTRA) or a long-acting muscarinic receptor antagonist (LAMA)<\/span> used in addition to moderate-dose MART<\/li><li>if control has not improved, stop the LTRA or LAMA and start a trial of the alternative medicine (LTRA or LAMA)<\/li><\/ul><\/li><\/ul><br \/>Step 5<br \/><ul><li><span class=\"concept\" data-cid=\"12292\">refer people to a specialist in asthma care<\/span> when asthma is not controlled despite treatment with moderate-dose MART, and trials of an LTRA and a LAMA<\/li><\/ul><br \/><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd602b.png\" data-fancybox=\"gallery\" data-caption=\"Algorithm showing pharmacological management of asthma in people aged 12 years and over\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd602.png\" alt=\"\" \/><\/a><\/div><\/div><\/div><br \/><h5 class='notes-heading'>Transferring people aged 12 and over from other treatment pathways<\/h5><br \/>There will be many people whose asthma was managed according to the previous guidelines that present with uncontrolled asthmatic symptoms. The guidelines give advice on how these people should be switched:  <a href='https:\/\/www.nice.org.uk\/guidance\/ng245\/chapter\/Recommendations#pharmacological-management-in-people-aged-12-and-over:~:text=asthma%20management.-,Transferring%20people%20aged%2012%20and%20over%20from%20other%20treatment%20pathways,-These%20recommendations%20are' title='NICE - 2024 Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)' target='_blank' class='badge rounded-pill text-bg-light deeplink'>NICE<\/a> <br \/><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th>Existing asthma treatment<\/th><th>New asthma treatment<\/th><\/tr><\/thead><tbody><tr><td>SABA as required only<\/td><td><span class=\"concept\" data-cid=\"12293\"> Low-dose ICS\/formoterol combination inhaler used as needed (as-needed AIR therapy)<\/span><\/td><\/tr><tr><td>SABA as required + regular low-dose ICS<br \/>SABA as required + regular low-dose ICS\/LABA <br \/>SABA as required + regular low-dose ICS + LTRA <br \/>SABA as required + regular low-dose ICS\/LABA + LTRA<\/td><td><span class=\"concept\" data-cid=\"12294\">Regular low-dose regular ICS\/formoterol combination inhaler (MART therapy)<\/span><\/td><\/tr><tr><td>SABA as required + regular moderate-dose ICS<br \/>SABA as required + regular moderate-dose ICS\/LABA  <br \/>SABA as required + regular moderate-dose ICS + LTRA or LAMA<br \/>SABA as required + regular moderate-dose ICS\/LABA + LTRA or LAMA<\/td><td>Regular moderate-dose MART therapy<\/td><\/tr><tr><td>Treatment regime containing a high-dose ICS<\/td><td>Refer to a respiratory specialist<\/td><\/tr><\/tbody><\/table><\/div>","notes_hash":"b11ce0ccb8c27014563f244a47ea595b","knowledge_graph_node_id_link":11377,"links":"<table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_2123\" data-linkid=\"2123\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_2123\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">48<\/span><button type=\"button\" style=\"\" id=\"link_dislike_2123\" data-linkid=\"2123\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_2123\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">11<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng245\/chapter\/Recommendations\">2024 Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/hjdIyyC8T-E\" data-description=\"Inhaler and Nebuliser Explanation\" data-upvotes=\"3\" data-downvotes=\"1\" data-media=\"131\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/hjdIyyC8T-E\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/hjdIyyC8T-E\" data-description=\"Inhaler and Nebuliser Explanation\" data-upvotes=\"3\" data-downvotes=\"1\" data-media=\"131\">Inhaler and Nebuliser Explanation<\/a><\/td><\/tr><tr><td><span ><small>Oxford Medical Education - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_225\" data-mediaid=\"225\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_225\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">3<\/span><button type=\"button\" style=\"\" id=\"media_dislike_225\" data-mediaid=\"225\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_225\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1<\/span><\/td><\/tr><\/table>","concepts_for_notes":{"12286":{"concept_text":"Asthma: adults and children \u2265 12 years first-line treatment --> low-dose inhaled corticosteroid (ICS)\/formoterol combination inhaler as required","concept_percentile":"55"},"12287":{"concept_text":"Asthma: adults and children \u2265 12 years second-line treatment --> low-dose inhaled corticosteroid (ICS)\/formoterol combination inhaler regularly and as required (MART)","concept_percentile":"35"},"12288":{"concept_text":"Asthma: adults and children \u2265 12 years not controlled on low-dose MART --> moderate-dose MART\n","concept_percentile":"27"},"12289":{"concept_text":"Asthma: adults not controlled on moderate-dose MART --> check the FeNO level if available, and the blood eosinophil count","concept_percentile":"36"},"12290":{"concept_text":"Asthma: adults not controlled on moderate-dose MART - if either FeNO level or blood eosinophil raised then --> refer to a respiratory specialist","concept_percentile":"35"},"12291":{"concept_text":"Asthma: adults not controlled on moderate-dose MART - if neither FeNO level nor blood eosinophil raised -->  trial of either a LTRA or a LAMA","concept_percentile":"49"},"12292":{"concept_text":"Refer adults to a respiratory specialist when asthma is not controlled despite treatment with moderate-dose MART, and trials of an LTRA and a LAMA","concept_percentile":"20"},"12294":{"concept_text":"Adults with asthma who are poorly controlled on SABA prn + regularly ICS --> regular low-dose regular ICS\/formoterol combination inhaler (MART therapy)","concept_percentile":"100"},"12295":{"concept_text":"If an adult presents with highly symptomatic asthma (for example, regular nocturnal waking) or with a severe exacerbation then treat the acute symptoms and start MART","concept_percentile":"100"}},"category_name":"Respiratory","subcategory_name":"","comment_count":24},"",[]]